ACH 4471

Drug Profile

ACH 4471

Alternative Names: ACH-0144471; ACH-4471

Latest Information Update: 23 Jan 2017

Price : $50

At a glance

  • Originator Achillion Pharmaceuticals
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Complement factor D inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glomerulonephritis; Paroxysmal nocturnal haemoglobinuria
  • Preclinical Haemolytic uraemic syndrome

Most Recent Events

  • 09 Jan 2017 Achillion Pharmaceuticals and Clinical Network Services plan a screening study for Paroxysmal nocturnal haemoglobinuria (Treatment-naive) in New Zealand (ACTRN12617000023358)
  • 01 Aug 2016 Achillion Pharmaceuticals initiates a phase I trial for Glomerulonephritis (In volunteers) and Paroxysmal nocturnal haemoglobinuria (In volunteers) in New Zealand (PO, Capsule and PO, Tablet) (ACTRN12616001017415)
  • 01 Aug 2016 Phase-I clinical trials in Glomerulonephritis (In volunteers) in New Zealand (PO) (Achillion Pharmaceuticals pipeline, July 2016; ACTRN12616001017415)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top